Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nicholas M. Boulis"'
Autor:
Thais Federici, Brooke R. Snyder, Bethwel Raore, Michele A. Kliem, Christina Krudy, Nicholas M. Boulis, Eric T. Quach, Colin K. Franz
Publikováno v:
PLoS ONE
PLoS ONE, Vol 4, Iss 10, p e7357 (2009)
PLoS ONE, Vol 4, Iss 10, p e7357 (2009)
Background: Amyotrophic Lateral Sclerosis (ALS) is neurodegenerative disease characterized by muscle weakness and atrophy due to progressive motoneuron loss. The death of motoneuron is preceded by the failure of neuromuscular junctions (NMJs) and axo
Autor:
Orion P Keifer, Juanmarco Gutierrez, Mark T Butt, Sarah D Cramer, Raymond Bartus, Malu Tansey, Daniel Deaver, Alexandre Betourne, Nicholas M Boulis
Publikováno v:
PLoS ONE, Vol 18, Iss 8, p e0277718 (2023)
Riluzole is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis (ALS). However, oral riluzole efficacy is modest at best, further it is known to have large inter-individual variability of serum concentration an
Externí odkaz:
https://doaj.org/article/7df620d86c554759a272218b0a7868ed
A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.
Autor:
Colin K Franz, Eric T Quach, Christina A Krudy, Thais Federici, Michele A Kliem, Brooke R Snyder, Bethwel Raore, Nicholas M Boulis
Publikováno v:
PLoS ONE, Vol 4, Iss 10, p e7357 (2009)
BACKGROUND:Amyotrophic Lateral Sclerosis (ALS) is neurodegenerative disease characterized by muscle weakness and atrophy due to progressive motoneuron loss. The death of motoneuron is preceded by the failure of neuromuscular junctions (NMJs) and axon
Externí odkaz:
https://doaj.org/article/90b32f7c00244afcb29f10012761057f